Description
Obesity and type 2 diabetes (T2DM) are two major risk factors for renal disease. The term Diabesity is used to describe the close relationship between T2DM and obesity and their common metabolic and pathogenic pathways. Worldwide, more than 400 million people have T2DM and about 2 billion subjects are overweight or obese. The fast growing prevalence of both T2DM and obesity makes diabesity an important challenge in nephrology. Obese patients frequently present the two main causes of end stage renal disease in developed countries, T2DM and hypertension. Moreover, obesity itself can cause specific renal diseases (such as obesity-related glomerulopathy) or increase the risk of progression of kidney diseases irrespective of the underlying cause. The pathogenetic pathways through which obesity causes/worsens renal disease are not completely known, although some possible explanations have been put forward. Are we closer to understanding the physiopathology of diabesity? Along with a small number of drugs, weight loss, by surgical and non-surgical interventions, has been tried in patients with diabesity, with some promising results in kidney damage prevention and treatment. Who benefits from these interventions? During the last 2 or 3 years new antidiabetic drugs showed promising results regarding its renal protective effects. What expectations can we have in these new drugs?
Course content